Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer—final results of the EUCROSS trial

In 2019, we reported the first efficacy and safety analysis of EUCROSS, a phase II trial investigating crizotinib in ROS1 fusion-positive lung cancer. At that time, overall survival (OS) was immature and the effect of crizotinib on intracranial disease control remained unclear. Here, we present the...

Full description

Bibliographic Details

Published in:	ESMO open Vol. 9; no. 2; p. 102237
Main Authors:	Michels, S., Massutí, B., Vasyliv, I., Stratmann, J., Frank, J., Adams, A., Felip, E., Grohé, C., Rodriguez-Abreu, D., Bischoff, H., Carcereny i Costa, E., Corral, J., Pereira, E., Fassunke, J., Fischer, R.N., Insa, A., Koleczko, S., Nogova, L., Reck, M., Reutter, T., Riedel, R., Schaufler, D., Scheffler, M., Weisthoff, M., Provencio, M., Merkelbach-Bruse, S., Hellmich, M., Sebastian, M., Büttner, R., Persigehl, T., Rosell, R., Wolf, J.
Format:	Journal Article
Language:	English
Published:	England Elsevier Ltd 01-02-2024 Elsevier
Subjects:	crizotinib EUCROSS lung cancer Original Research overall survival ROS1 lung cancer EUCROSS overall survival crizotinib ROS1
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!